NCT02660905 - HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

June 30, 2018

Conditions

Human Immunodeficiency VirusHepatitis C, Chronic

Interventions

DRUG

E/C/F/TAF;

Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy

DRUG

Ledipasvir-Sofosbuvir

Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy

Trial Locations (2)

The Ottawa Hospital, General Campus, Ottawa

The Research Institute of the McGill University Health Centre, Montreal